Find the lowest price from 7,500+ FDA-registered pharmacies. Save up to 90%.
⭐ 4.7/5 Customer Rating
🏅 FDA-Registered Pharmacies
Prevents mast cells from degranulating — stopping the release of histamine, leukotrienes, and other inflammatory mediators before they trigger symptoms.
Blocks histamine H1 receptors directly at target tissues — a second line of action that manages symptoms even when some mediator release occurs.
Tirzepatide combined with B12 (methylcobalamin) pairs the dual GIP/GLP-1 receptor agonist with essential vitamin B12 support. B12 is added to address nutrient depletion from reduced food intake and to support energy, neurological health, and metabolism during treatment.
Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Tirzepatide is a dual GIP and GLP-1 receptor agonist — it activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism produces greater appetite suppression and metabolic improvement than GLP-1 activation alone. Methylcobalamin (B12) supports methylation, red blood cell production, and nerve function that may be affected by significantly reduced caloric intake.
No commercially available product combines tirzepatide with B12. Compounding allows prescribers to deliver both agents in a single injection, address nutrient depletion from aggressive appetite suppression, and offer custom titration schedules not available with branded Mounjaro or Zepbound.
Compounded tirzepatide with B12 combines the most potent weight-loss injectable currently available with methylcobalamin — the bioactive form of vitamin B12. Tirzepatide's dual GIP/GLP-1 mechanism delivers superior weight loss compared to single-receptor GLP-1 agonists like semaglutide, but the more aggressive appetite suppression also increases the risk of nutrient depletion.
Clinical trials showed tirzepatide patients lost up to 22.5% of body weight at the highest dose. With that level of caloric restriction, B12 and other micronutrient deficiencies become a meaningful clinical concern. Adding methylcobalamin to the compounded preparation addresses this proactively.
This combination is prepared by licensed compounding pharmacies as a patient-specific preparation under a valid prescription from a licensed provider.
Tirzepatide — Dual GIP/GLP-1 Receptor Activation
Tirzepatide is a synthetic peptide that activates both GIP and GLP-1 receptors. GIP receptor activation enhances insulin sensitivity in adipose tissue and may contribute to fat mobilization. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion. The dual mechanism produces additive metabolic effects that exceed either pathway alone.
Methylcobalamin — Neurological and Metabolic Support
Methylcobalamin is the bioactive coenzyme form of B12, essential for the methionine synthase reaction in the methylation cycle. It supports myelin sheath integrity, homocysteine metabolism, red blood cell maturation, and DNA synthesis. Patients on tirzepatide with significantly reduced food intake are at increased risk for B12 insufficiency.
Prescribed for patients with a documented clinical need for compounded tirzepatide who also benefit from B12 supplementation:
BIND THIS TO: Mechanism Text CMS field (Rich Text). Then delete this paragraph and add a Rich Text element instead.
Metabolic syndrome, PCOS (insulin resistance component), non-alcoholic fatty liver disease (NAFLD), cardiovascular risk reduction
⚠️ Dosing should be determined by your prescriber. The information below is general guidance only.
Typical tirzepatide titration with B12:
Weeks 1–4: Tirzepatide 2.5mg + B12 1mg weekly
Weeks 5–8: Tirzepatide 5mg + B12 1mg weekly
Weeks 9–12: Tirzepatide 7.5mg + B12 1mg weekly
Weeks 13–16: Tirzepatide 10mg + B12 1mg weekly
Weeks 17+: Tirzepatide 12.5–15mg + B12 1mg weekly (as tolerated)
Dosing is individualized by the prescribing provider. B12 dose typically remains constant while tirzepatide is titrated upward.
Tirzepatide requires careful titration starting at 2.5mg with dose increases every 4 weeks. GI side effects (nausea, diarrhea, constipation) are the primary dose-limiting factor. The B12 component does not contribute to side effects and may help with energy during titration. Patients who cannot tolerate dose increases should remain at their current tolerated dose rather than pushing higher.
Subcutaneous Injection — The standard and best-studied form. Tirzepatide and B12 are combined in a single vial for weekly injection.
Sublingual Tablets — A needle-free alternative dissolved under the tongue. Bioavailability may differ from injectable delivery. Less clinical data exists for sublingual tirzepatide compared to injection.
From tirzepatide (most common):
From B12 (methylcobalamin):
GI side effects typically improve with continued use and gradual titration. Report persistent vomiting, severe abdominal pain, or signs of pancreatitis to your provider immediately.
Compounded tirzepatide + B12 is a 503A patient-specific preparation requiring a valid prescription. The FDA resolved the tirzepatide shortage in late 2024; compounding remains legal for patients with documented clinical needs that cannot be met by the commercial product. Patients should verify their pharmacy is licensed and conducts third-party sterility and potency testing.
Tirzepatide activates both GIP and GLP-1 receptors (dual agonist), while semaglutide activates only GLP-1 receptors. Clinical trials showed tirzepatide produced greater weight loss — up to 22.5% of body weight at the highest dose compared to approximately 15% with semaglutide. Your prescriber can help determine which is appropriate for your clinical needs.
Tirzepatide causes significant appetite suppression, which can lead to reduced food intake and nutrient gaps. Methylcobalamin (B12) supports energy production, nerve health, and red blood cell formation. Combining both in one injection simplifies the treatment regimen and proactively addresses a common deficiency risk.
No. Compounded medications are not individually FDA-approved. However, tirzepatide is the same active ingredient in FDA-approved Mounjaro and Zepbound, and methylcobalamin is a well-established nutrient. The combination is prepared by licensed compounding pharmacies under a valid prescription.
Typical pricing ranges from $199 to $499 per month depending on the tirzepatide dose and pharmacy. This is substantially less than branded Mounjaro or Zepbound without insurance. Compounding Finder helps you compare options from multiple licensed pharmacies.
Yes. Compounded tirzepatide + B12 requires a valid prescription from a licensed healthcare provider. Avoid any source offering tirzepatide without a prescription requirement.
1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
2. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
3. Pflipsen MC, et al. The Prevalence of Vitamin B12 Deficiency in Patients with Type 2 Diabetes. J Am Board Fam Med. 2009;22(5):528-534.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
Prevents mast cells from degranulating — stopping the release of histamine, leukotrienes, and other inflammatory mediators before they trigger symptoms.
